PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis

This network meta-analysis (NMA) evaluates the safety of first-line programmed death-ligand 1 (PD-L1) inhibitor monotherapy in advanced NSCLC patients compared to platinum-based chemotherapy. We also compared the risk of adverse events (AEs) according to programmed cell death-1 receptor (PD-1) or PD...

Full description

Bibliographic Details
Main Authors: María Rosario García Campelo, Edurne Arriola, Begoña Campos Balea, Marta López-Brea, José Fuentes-Pradera, Javier de Castro Carpeno, Carlos Aguado, Diego Pérez Parente, Fidel de Oro Pulido, Pedro Ruiz-Gracia, Delvys Rodríguez-Abreu
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Journal of Clinical Medicine
Subjects:
non-small cell lung cancer
network meta-analysis
immunotherapy
first-line treatment
PD-L1 inhibitors
safety
Online Access:https://www.mdpi.com/2077-0383/10/19/4583

Internet

https://www.mdpi.com/2077-0383/10/19/4583

Similar Items